RT Journal Article
SR Electronic
T1 Tau pathology mediates the effects of amyloid on neocortical tau propagation and neurodegeneration among individuals without dementia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.01.21259866
DO 10.1101/2021.07.01.21259866
A1 Murat Bilgel
A1 Dean F. Wong
A1 Abhay R. Moghekar
A1 Luigi Ferrucci
A1 Susan M. Resnick
A1 for the Alzheimer’s Disease Neuroimaging Initiative
YR 2021
UL http://medrxiv.org/content/early/2021/07/06/2021.07.01.21259866.abstract
AB Amyloid is associated with greater tau pathology and is thought to facilitate tau propagation from medial temporal lobe (MTL) to the neocortex, where tau is closely associated with local neurodegeneration. We used causal mediation analysis to quantify the involvement of amyloid and tau in tau propagation and neurodegeneration, as measured by cerebral blood flow, glucose metabolism, and volume, in two longitudinal samples of individuals without dementia. Greater entorhinal tau was associated with greater inferior temporal tau. This association was stronger among amyloid+ individuals, suggesting that amyloid facilitates tau propagation from MTL to neocortex. Entorhinal tau mediated up to 50% of the total effect of amyloid on inferior temporal tau. Higher inferior temporal tau was associated with colocalized neurodegeneration, including lower cerebral blood flow, glucose metabolism, and regional volume, whereas amyloid had only an indirect effect on neurodegeneration via tau, implying that tau is the primary driver of neurodegeneration. Our findings suggest targeting amyloid or MTL tau might slow down neocortical spread of tau, but a combination therapy may yield better outcomes.Competing Interest StatementMB, LF, ARM, and SMR declare that they have no competing interests. DFW is a former President of the Brain Imaging Council of the Society of Nuclear Medicine and Molecular Imaging. DFW receives contract funding from LB Pharmaceuticals and in-kind contributions from Roche Neuroscience, Avid Radiopharmaceuticals/Eli Lilly and Company, and Cerveau Technologies. Funding StatementThis study was supported by the Intramural Research Program of the National Institute on Aging, NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The BLSA research protocols were conducted in accordance with United States federal policy for the protection of human research subjects contained in Title 45 Part 46 of the Code of Federal Regulations (45 CFR 46), approved by local institutional review boards (IRB), and all participants gave written informed consent at each visit. The BLSA PET substudy is governed by the IRB of the Johns Hopkins Medical Institutions, and the BLSA study is overseen by the National Institute of Environmental Health Sciences IRB. The ADNI study was approved by the IRBs of all of the participating institutions, and all participants gave written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode for performing statistical analyses and generating figures is provided in an open repository (https://gitlab.com/bilgelm/tau_amyloid_neurodegeneration). Data from the BLSA are available upon request from the BLSA website (https://www.blsa.nih.gov). All requests are reviewed by the BLSA Data Sharing Proposal Review Committee. A deidentified version (with age bands instead of continuous age and excluding APOE genotype) of the cross-sectional BLSA data used in the statistical analyses is publicly available (https://doi.org/10.7910/DVN/YFJAZO). Data from the ADNI are available from the ADNI website (adni.loni.usc.edu). https://doi.org/10.7910/DVN/YFJAZO http://adni.loni.usc.edu https://www.blsa.nih.gov